<DOC>
	<DOCNO>NCT02211690</DOCNO>
	<brief_summary>This study aim describe proportion participant non-occupational post-exposure prophylaxis ( NPEP ) failure , define NPEP non-completion ( include loss follow-up ) week 4 primary HIV infection week 4 12 , exclude participant cease study drug : 1 . The participant find HIV-infected ( study drug cease genotype infecting strain determine ) 2 . The source find HIV-uninfected The primary study objective : 1 . To describe on-drug adherence regimen completion rate 28 day NPEP use dolutegravir ( DTG ) co-formulated emtricitabine-tenofovir ( FTC-TDF ) 2 . To describe safety 28 day non-occupational post-exposure prophylaxis ( NPEP ) use dolutegravir co-formulated emtricitabine-tenofovir The study multi-site , prospective , open-label , non-randomized trial . One-hundred ( 100 ) eligible participant receive dolutegravir ( one tablet ) co-formulated emtricitabine-tenofovir , two tablet , daily 28 day base one follow exposure : 1. receptive anal intercourse source know HIV-infected ; 2. receptive anal intercourse source unknown HIV status ; 3. insertive anal intercourse source know HIV-infected There 7 study visit 12-week period . Follow-up post NPEP 8 week i.e . week-12 post-exposure . Any participant intolerant dolutegravir manage investigator 's discretion .</brief_summary>
	<brief_title>The Tolerability , Adherence , Dolutegravir With Co-formulated Tenofovir-emtricitabine HIV Non-occupational Post-exposure Prophylaxis</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>1 . Man sex men 2 . Age least 18 year 3 . Potential HIV exposure follow : receptive anal intercourse source know HIVinfected ; receptive anal intercourse source unknown HIV status ; insertive anal intercourse source know HIVinfected 4 . Able provide write , inform consent 5 . Able commit study visit 1 . Nonsexual exposure 2 . Exposure occur sex man woman 3 . HIV infection diagnose baseline testing ( antibody , Western blot , proviral DNA ) include indeterminate serology consistent possible primary HIV infection 4 . Use medication contraindicate DTG , FTC TDF 5 . Use medication effect concentration dolutegravir / concomitant drug include : oxcarbazepine , phenytoin , phenobarbital , carbamazepine , rifampicin , metformin St. John 's wort ( St John 's wort stop 28day period NPEP ) . 6 . History presence allergy DTG , FTC , TDF components 7 . Alanine aminotransferase ( ALT ) ≥5 time upper limit reference range ALT ≥3 time bilirubin ≥1.5 time upper limit reference range 8 . Unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminaemia , oesophageal gastric varix , persistent jaundice ) know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) 9 . Severe hepatic impairment ( Class C ) determine ChildPugh classification 10 . Serum estimate Glomerular Filtration Rate ( eGFR ) &lt; 60 mL/min/BSAc 11 . Current therapy hepatitis B infection 12 . Serological evidence chronic/active hepatitis B 13 . Previous OPEP/NPEP contain DTG 14 . A participant history current evidence condition , therapy , laboratory abnormality , circumstance might confound result study , interfere participant 's participation full duration study 15 . Unable complete study procedure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>